Chicago, IL (PRWEB) March 28, 2014
The prescription drug safety center DrugRisk.com is announcing updated legal news on the site for patients taking the blood thinner Pradaxa. Recent court documents show a federal court has scheduled the first lawsuit alleging the drug caused internal bleeding injury or death to start in September*.
DrugRisk is a free resource providing the latest recalls, safety alerts, research and legal news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
Pradaxa was approved by the FDA in 2010 to prevent blood clots and strokes in patients with atrial fibrillation. Experts disagree, however, whether it increases risks of internal bleeding.
The resource center has added research indicating patients taking newer blood thinners like dabigatran may be 55% more likely to suffer internal bleeding**. The Institute for Safe Medication Practices has also advised bleeding from Pradaxa could be 5 times as likely to cause death***.
The FDA recently announced a new study to compare the safety of Pradaxa and the traditional blood thinning medication warfarin****.
Due to the number of families that have filed a Pradaxa lawsuit alleging internal bleeding, cases have been consolidated in a special federal multidistrict litigation court. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. The latest court records show 2,226 lawsuits pending*****.
Now, DrugRisk has learned that U.S. District Judge David Herndon, who is presiding over the cases, has scheduled the first Pradaxa trial to begin on September 8, 2014*.
Anyone who suffered internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com or speak with a lawyer about their legal options. Due to the complex nature of these cases, DrugRisk only recommends lawyers who have already handled Pradaxa lawsuits.
Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer.
*U.S. District Judge David Herndon Pretrial Order 3/5/14, (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
**Gastroenterology, July 2013; gastrojournal.org/article/S0016-5085(13)00290-4/fulltext
***Institute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf
****Forbes, 1/3/14; forbes.com/sites/larryhusten/2014/01/03/fda-plans-new-safety-assessment-of-dabigatran-pradaxa/
*****JPML, 3/13/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-March-13-2014.pdf